Term ended no later than Nov 22, 2025 · Medium confidence
20-year base term ended Nov 22, 2025
Held by Adamas Pharmaceuticals, Inc.
Filed Nov 22, 2005 as application 11/285,905 · Granted Nov 17, 2009
Base term, 20 years from filing
Today
Ended no later than Nov 22, 2025
2005
2026
Clock starts
Nov 22, 2005
Nov 22, 2005
Ended no later than
Nov 22, 2025
Nov 22, 2025
Granted
Nov 17, 2009
Nov 17, 2009
base term
after the term ends
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
43
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. All three maintenance fees were paid, so no fee lapse ended it. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 22, 2005, when this application, 11/285,905, was filed | Nov 22, 2025 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | term ended | High confidence |
| Computed term end | The steps above, in order | no later than Nov 22, 2025 | Medium confidence |
This family
| US 6,620,845 | Lapsed on the fee record Sep 2015 | Sep 2015 |
| Application 60/630,885 | Provisional application no patent term | no patent term |
| US 7,326,730 | Term ended Feb 2020 | Feb 2020 |
| US 7,619,007 | this patent no later than Nov 2025 | no later than Nov 2025 |
| US 8,058,291 | In force Dec 2029 | Dec 2029 |
| Application PCT/US2006/013506 | PCT application no patent term | no patent term |
| Application PCT/US2007/011887 | PCT application no patent term | no patent term |
| US 8,168,209 | Term ended Jul 2026 | Jul 2026 |
8 of 43 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Mar 7, 2006 Reel 17648, frame 618 | Went, Gregory T.; Fultz, Timothy; Porter, Seth; Meyerson, Laurence R.; Burkoth, Timothy S. | Neuromolecular Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Oct 2, 2007 Reel 19959, frame 266 | Neuromolecular Pharmaceuticals, Inc. | Adamas Pharmaceuticals, Inc. | Change of Name |
| Jun 6, 2017 Reel 42704, frame 254 | Adamas Pharmaceuticals, Inc. | Adamas Pharma, LLC | Assignment of Assignor's Interest |
| Nov 29, 2017 Reel 44538, frame 562 | Neuromolecular, Inc. | Neuromolecular Pharmaceuticals, Inc. | Change of Name |
| Nov 29, 2017 Reel 44548, frame 480 | Neuromolecular Pharmaceuticals, Inc. | Adamas Pharmaceuticals, Inc. | Change of Name |
| Oct 28, 2020 Reel 54246, frame 890 | Went, Gregory T.; Fultz, Timothy J.; Porter, Seth; Meyerson, Laurence R.; Burkoth, Timothy S. | Neuromolecular, Inc. | Corrective Assignment to Correct the Name of the Assignee to from Neuromolecular Pharmaceuticals, Inc. to Neuromolecular, Inc. Previously Recorded on Reel 017648 Frame 0618. Assignor(S) Hereby Confirms the Assignment. |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Note
A terminal disclaimer is on file and its reference is not resolved. No cap is applied and none is guessed
Open question
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Nov 22, 2025. We will not guess the cap.
Citations
83
later US patents cite this one
That is top 10% of utility patents granted in 2009 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
This computed term ends no later than the date shown; an unresolved terminal disclaimer may end it earlier. Related patents and pending applications may cover overlapping subject matter.